Advertisement

Advertisement

Expertâ€™s Corner

Advertisement

Advertisement

Jun

25

Today In Oncology

Exposure to Specific Carcinogens and Prostate Cancer Risk Among World Trade Center First Responders

Comparison of Combination Dosing Schedules of Neoadjuvant Ipilimumab/Nivolumab in Macroscopic Stage III Melanoma

Are Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma Common?

Immune Response to HPV16-Driven Tumorigenesis May Be Detectable Before Clinical Diagnosis of Oropharyngeal Squamous Cell Carcinoma

Study Finds Primary Care Providers Are Engaged in Cancer Survivorship Care but Report Barriers to Optimal Care Delivery

;

Advertisement

Most Read Stories

'Oral Cryotherapy' for Patients Undergoing Oxaliplatin-Based Chemotherapy

Rate and Outcome of Late Relapses in Patients With DLBCL Treated With Immunochemotherapy

PERSEPHONE: 4-Year Disease-Free Survival With 6 vs 12 Months of Adjuvant Trastuzumab for HER2-Positive Breast Cancer

KEYNOTE-001: 5-Year Overall Survival With Pembrolizumab in Advanced NSCLC

2019 ASCO: 3-Year Outcomes in the KRISTINE Trial on Neoadjuvant Trastuzumab Emtansine Plus Pertuzumab in HER2-Positive Breast Cancer

Most Viewed Videos

Matthew A. Powell, MD, and Don S. Dizon, MD, on Uterine or Ovarian Cancer: Paclitaxel Plus Carboplatin vs Ifosfamide in Chemotherapy-Naive Patients

Jason Westin, MD, on Diffuse Large B-Cell Lymphoma: Rituximab, Lenalidomide, and Ibrutinib Prior to Chemotherapy

Peter Schmid, MD, PhD, and Hope S. Rugo, MD, on Breast Cancer: Next Steps in Immunotherapy

Thomas J. George, MD, on Locally Advanced Rectal Cancer: Total Neoadjuvant Therapy

Miriam Knoll, MD, and Zachery Reichert, MD, PhD, on Prostate Cancer: Focal Radiation for Oligometastatic Castration-Resistant Disease

© 2019 HSP News Service, L.L.C.